Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-29
- Target Recruit Count
- 18
- Registration Number
- NCT00000818
- Locations
- 🇺🇸
Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Baylor College of Medicine / Houston Veterans Adm Med Ctr, Houston, Texas, United States
🇺🇸Univ of Illinois, Chicago, Illinois, United States
A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-15
- Target Recruit Count
- 18
- Registration Number
- NCT00001007
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States
🇺🇸Stanford Univ School of Medicine, Stanford, California, United States
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 45
- Registration Number
- NCT00000703
- Locations
- 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 94
- Registration Number
- NCT00001095
- Locations
- 🇺🇸
St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States
🇺🇸Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 55
- Registration Number
- NCT00001075
- Locations
- 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 12
- Registration Number
- NCT00001002
- Locations
- 🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸Unc Aids Crs, Chapel Hill, North Carolina, United States
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 3200
- Registration Number
- NCT00000736
- Locations
- 🇺🇸
Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States
🇺🇸Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States
🇺🇸SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000920
- Locations
- 🇺🇸
Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Children's Hosp of Michigan, Detroit, Michigan, United States
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00002190
- Locations
- 🇺🇸
Davies Med Ctr / c/o HIV Institute, San Francisco, California, United States
🇺🇸Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸Pacific Oaks Med Group / Rsch & Scientific Investigation, Sherman Oaks, California, United States
A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 654
- Registration Number
- NCT00001029
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.